Almost two years of treatment with Kaftrio (elexacaftor, tezacaftor, and ivacaftor) did not affect liver stiffness — an indicator…
Articles by Andrea Lobo, PhD
Inogen has acquired Physio-Assist, including Simeox, a technology for airway clearance and mucus management in people with…
Infections with Staphylococcus aureus small colony variants, known as SCVs, are highly prevalent in people with cystic fibrosis (CF) —…
An increase in body mass index (BMI) in people with cystic fibrosis (CF) under Kaftrio therapy may not…
Anxiety and depression are more likely in younger cystic fibrosis (CF) patients with CF-related diabetes and more evident…
The first patient has been dosed in a Phase 1 clinical trial of KB407, Krystal Biotech’s investigational gene therapy…
The presence of intestinal metabolites called bile acids in the airways of 1-year-old children genetically diagnosed with cystic fibrosis…
Kaftrio (elexacaftor, tezacaftor, and ivacaftor) safely and effectively eases structural lung damage and improves lung function and the quality of…
Antibiotic resistance is high among cystic fibrosis (CF) patients infected with Staphylococcus aureus (S. aureus), according to a recent…
Reducing the dose of Kaftrio (elexacaftor, tezacaftor, and ivacaftor) should be considered for cystic fibrosis (CF) patients who…